2021 / 03

Next Paper
DOI: 10.24075/brsmu.2021.030

ORIGINAL RESEARCH

Changes in plasma sphingolipid levels against the background of lipid-lowering therapy in patients with premature atherosclerosis

Rogozhina AA1,2, Alessenko AV3, Kurochkin IN3, Minushkina LO1, Gutner UA3, Shupik MA3, Maloshitskaya OA4, Lebedev AT4, Zateyshchikov DA1,2
About authors

1 Central State Medical Academy of the Department of Presidential Affairs of the Russian Federation, Moscow, Russia

2 City Clinical Hospital № 51, Moscow, Russia

3 Institute of Biochemical Physics named after N. M. Emanuel, Moscow, Russia

4 Lomonosov Moscow State University, Moscow, Russia

Correspondence should be addressed: Larisa O. Minushkina
Marshala Timoshenko, 19, str. 1А, Moscow, 121359; ur.liam@anikhsunim

About paper

Funding: RFBR grant 19-04-00870А, Sphingolipidome Analysis of Cardiovascular Disease Markers.

Author contribution: Rogozhina AA — sampling, data acquisition; Alessenko AV — project management; Kurochkin IN — data analysis; Minushkina LO — data analysis, manuscript writing; Gutner UA, Shupik MA, Maloshitskaya OA — sample preparation, laboratory tests, data analysis; Lebedev AT, Zateyshchikov DA — study planning, data analysis, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of City Clinical Hospital № 51, Moscow (protocol № 02/19 dated February 7, 2019). Informed consent was submitted by all patients.

Received: 2021-05-24 Accepted: 2021-06-13 Published online: 2021-06-23
|
  1. Bossard M, Latifi Y, Fabbri M, Kurmann R, Brinkert M, Wolfrum M, et al. Increasing Mortality From Premature Coronary Artery Disease in Women in the Rural United States. J Am Heart Assoc. 2020; 9 (9): e015334. DOI: 10.1161/JAHA.119.015334.
  2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al; ESC Scientific Document Group. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111–88. DOI: 10.1093/eurheartj/ehz455.
  3. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38 (32): 2459–72. DOI: 10.1093/eurheartj/ehx144.
  4. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016; 67 (22): 2578–89. DOI: 10.1016/j.jacc.2016.03.520.
  5. Barenholz Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell Biochem. 2004; 37: 167–215. DOI: 10.1007/978-1-4757-5806-1_5.
  6. Manicke NE, Nefliu M, Wu C, Woods JW, Reiser V, Hendrickson RC, et al. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal Chem. 2009; 81 (21): 8702–7. DOI: 10.1021/ac901739s.
  7. Brunkhorst R, Friedlaender F, Ferreirós N, Schwalm S, Koch A, Grammatikos G, et al. Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine. Neural Plast. 2015; 2015: 503079. DOI: 10.1155/2015/503079.
  8. Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016; 37 (25): 1967–76. DOI: 10.1093/eurheartj/ehw148.
  9. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37 (8): 911–7.
  10. Vasile VC, Meeusen JW, Medina Inojosa JR, Donato LJ, Scott CG, Hyun MS, et al. Ceramide Scores Predict Cardiovascular Risk in the Community. Arterioscler Thromb Vasc Biol. 2021; 41 (4): 1558–69. DOI: 10.1161/ATVBAHA.120.315530.
  11. Li Q, Wang X, Pang J, Zhang Y, Zhang H, Xu Z, et al. Associations between plasma ceramides and mortality in patients with coronary artery disease. Atherosclerosis. 2020; 314: 77–83. DOI: 10.1016/j. atherosclerosis.2020.09.004.
  12. Poss AM, Maschek JA, Cox JE, Hauner BJ, Hopkins PN, Hunt SC, et al. Machine learning reveals serum sphingolipids as cholesterolindependent biomarkers of coronary artery disease. J Clin Invest. 2020; 130 (3): 1363–76. DOI: 10.1172/JCI131838.
  13. You Q, Peng Q, Yu Z, Jin H, Zhang J, Sun W, et al. Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease. Biosci Rep. 2020; 40 (9): BSR20201519. DOI: 10.1042/ BSR20201519.
  14. Han JS, Kim K, Jung Y, Lee JH, Namgung J, Lee HY, et al. Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin. Sci Rep. 2018; 8 (1): 14642. DOI: 10.1038/s41598018-33058-x.
  15. Snowden SG, Grapov D, Settergren M, D'Alexandri FL, Haeggström JZ, Fiehn O, et al. High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy. Circ Cardiovasc Genet. 2014; 7 (6): 955–64. DOI: 10.1161/CIRCGENETICS.114.000606.
  16. Ng TW, Ooi EM, Watts GF, Chan DC, Weir JM, Meikle PJ, et al. Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J Clin Endocrinol Metab. 2014; 99 (11): E2335–40. DOI: 10.1210/jc.2014-1665.
  17. Ng TW, Ooi EM, Watts GF, Chan DC, Meikle PJ, Barrett PH. Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment. J Clin Endocrinol Metab. 2015; 100 (6): 2497–501. DOI: 10.1210/jc.2014-4348.
  18. Feder S, Wiest R, Weiss TS, Aslanidis C, Schacherer D, Krautbauer S, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis. Lipids Health Dis. 2021; 20 (1): 6. DOI: 10.1186/s12944-021-01431-x.
  19. Hilvo M, Simolin H, Metso J, Ruuth M, Öörni K, Jauhiainen M, et al. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. Atherosclerosis. 2018; 269: 159–65. DOI: 10.1016/j. atherosclerosis.2018.01.004.
  20. Ye Q, Svatikova A, Meeusen JW, Kludtke EL, Kopecky SL. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels. Am J Cardiol. 2020; 128: 163–7. DOI: 10.1016/j.amjcard.2020.04.052.
  21. Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014; 99 (1): E45–52. DOI: 10.1210/jc.2013– 2559.
  22. Instrukcija k preparatu Pralujent. Dostupno po ssylke: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e7885c43-2824-42ee-8673-f6221d7f2f5a&t=. Russian.